Coronavirus vaccine data from Pfizer unlikely to come before U.S. election


A health worker injects a person during clinical trials for a Covid-19 vaccine at Research Centers of America in Hollywood, Florida.

Eva Marie Uzcategui | Bloomberg | Getty Images

Crucial coronavirus vaccine data expected from Pfizer this week now appears unlikely to come before the U.S. election on Nov. 3.

On a call with investors Tuesday, Pfizer CEO Albert Bourla said that the company doesn’t expect to make any announcement on its trial until at least a week after the data and safety monitoring board conducts its review of the company’s phase three vaccine trial. The board, which will assess whether its trial with German drugmaker BioNTech has been successful, has not conducted an interim efficacy analysis yet, Pfizer said.

“Let’s all have patience,” Bourla said on the call. “I know how much the stress levels are growing. I know how much the vaccine is needed for the world.”

The phase three trials are a critical last step needed to get the vaccines cleared for distribution. Three other U.S.-backed candidates are in phase three: Moderna, AstraZeneca and Johnson & Johnson. Pfizer expects to apply for an emergency use authorization with the Food and Drug Administration next month.

Since early September, Bourla has repeatedly said the company could have late-stage vaccine trial data as early as October. The timeline drew concerns and skepticism from infectious disease experts and scientists who also feared a vaccine authorization could be influenced by politics, not science. President Donald Trump has insisted a Covid-19 vaccine could be ready before Election Day.

Earlier in the day, Pfizer said it had enrolled more than 42,000 volunteers in its late-stage trial. It said nearly 36,000 of the volunteers have already received the second of its two-dose Covid-19 vaccine. In September, Pfizer expanded the enrollment of its phase three trial to up to 44,000 volunteers from the initial target of up to 30,000. 

The vaccine contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus.

This is breaking news. Please check back for updates.



Source link

Discover

Sponsor

Latest

IPO process has gotten worse in last five years, says Bill Gurley

The massive pops during recent market debuts have proven the traditional IPO process has only gone downhill, Benchmark's Bill Gurley said Tuesday."The IPO...

WHO holds a briefing on the coronavirus as cases surge

https://www.youtube.com/watch?v=5aJrI4LyA_oThe World Health Organization is holding a briefing Monday on the coronavirus as the pandemic in the United States and Europe accelerates.On Saturday,...

Binge Drinking Soared During Lockdown: Survey

By Cara Murez HealthDay Reporter ...

2021 Volkswagen Arteon gets higher base price after refresh

The 2021 Volkswagen Arteon is rolling into dealers as we speak, and VW just announced official pricing for the updated model. Unfortunately, the...

Amazon resumes policy that dings workers for taking too many breaks

Amazon workers at Amazon's Staten Island warehouse strike in demand that the facility be shut down and cleaned after one staffer tested positive...